NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2019
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2019
SUMMARY
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. The latest report NT 3 Growth Factor Receptor - Pipeline Review, H1 2019, outlays comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation. The molecules developed by companies in Pre-Registration, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 2 respectively.
Report covers products from therapy areas Oncology, Genetic Disorders and Central Nervous System which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Central Nervous System (CNS) Tumor, Fibrosarcoma, Neuroblastoma, Papillary Thyroid Cancer, Salivary Gland Cancer, Thyroid Cancer, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Brain Tumor, Cervical Cancer, Charcot-Marie-Tooth Disease, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma and Synovial Sarcoma.
Furthermore, this report also reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. The latest report NT 3 Growth Factor Receptor - Pipeline Review, H1 2019, outlays comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation. The molecules developed by companies in Pre-Registration, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 2 respectively.
Report covers products from therapy areas Oncology, Genetic Disorders and Central Nervous System which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Central Nervous System (CNS) Tumor, Fibrosarcoma, Neuroblastoma, Papillary Thyroid Cancer, Salivary Gland Cancer, Thyroid Cancer, Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Brain Tumor, Cervical Cancer, Charcot-Marie-Tooth Disease, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma and Synovial Sarcoma.
Furthermore, this report also reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
- The report reviews NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles
CH-7057288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2019: Bayer announces results of sub-group analysis for Vitrakvi (larotrectinib) in patients with NTRK gene fusion-positive metastatic non-small cell lung cancer (NSCLC)
Apr 05, 2019: Handok, CMG apply for P1 trial for anticancer treatment candidate
Apr 01, 2019: Following milestone FDA Approval, MSK researchers address resistance to Larotrectinib through next-generation TRK-targeted therapeutic
Mar 15, 2019: Chugai files a New Drug Application for a ROS1/TRK inhibitor Entrectinib for the treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Feb 19, 2019: FDA grants priority review to Roche’s personalised medicine entrectinib
Jan 18, 2019: Chugai files an application for expanded use of genomic mutation analysis program “FoundationOne CDx Cancer Genomic Profile”
Dec 19, 2018: Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the treatment of NTRK Fusion-Positive Solid Tumors
Dec 06, 2018: Chugai receives orphan drug designation for Entrectinib in NTRK fusion-positive solid tumors
Dec 04, 2018: BC Cancer gene discovery leads to a new drug that targets 22 cancers
Nov 27, 2018: U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
Nov 26, 2018: New FDA-approved therapy targets a variety of cancers
Oct 21, 2018: Roches investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Oct 21, 2018: Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types
Oct 09, 2018: Bayer to showcase latest oncology research on larotrectinib at ESMO 2018 Congress
Oct 09, 2018: Loxo Oncology announces Presentation on larotrectinib at the European Society for Medical Oncology 2018 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles
CH-7057288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2019: Bayer announces results of sub-group analysis for Vitrakvi (larotrectinib) in patients with NTRK gene fusion-positive metastatic non-small cell lung cancer (NSCLC)
Apr 05, 2019: Handok, CMG apply for P1 trial for anticancer treatment candidate
Apr 01, 2019: Following milestone FDA Approval, MSK researchers address resistance to Larotrectinib through next-generation TRK-targeted therapeutic
Mar 15, 2019: Chugai files a New Drug Application for a ROS1/TRK inhibitor Entrectinib for the treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Feb 19, 2019: FDA grants priority review to Roche’s personalised medicine entrectinib
Jan 18, 2019: Chugai files an application for expanded use of genomic mutation analysis program “FoundationOne CDx Cancer Genomic Profile”
Dec 19, 2018: Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the treatment of NTRK Fusion-Positive Solid Tumors
Dec 06, 2018: Chugai receives orphan drug designation for Entrectinib in NTRK fusion-positive solid tumors
Dec 04, 2018: BC Cancer gene discovery leads to a new drug that targets 22 cancers
Nov 27, 2018: U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
Nov 26, 2018: New FDA-approved therapy targets a variety of cancers
Oct 21, 2018: Roches investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Oct 21, 2018: Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types
Oct 09, 2018: Bayer to showcase latest oncology research on larotrectinib at ESMO 2018 Congress
Oct 09, 2018: Loxo Oncology announces Presentation on larotrectinib at the European Society for Medical Oncology 2018 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AnHeart Therapeutics Inc, H1 2019
Pipeline by Bayer AG, H1 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Handok Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AnHeart Therapeutics Inc, H1 2019
Pipeline by Bayer AG, H1 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Handok Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
COMPANIES MENTIONED
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
COMPANIES MENTIONED
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
